Verrica Pharmaceuticals (VRCA)
Commercializes YCANTH for molluscum while developing additional dermatology treatments.
$5.75
Pre-market+0.33 (+6.09%)
At close$5.42(+3.44%)
Something off on this page? Send us feedback.
Next report
Nov 13, 2026
in 71 days
EPS estimate
−$0.50
Revenue estimate
$6.4M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.24−$1.00$0.02$0.13−$0.56−$0.41−$0.62Pending
Estimate−$0.25−$1.40−$0.70−$1.14−$0.43−$0.59−$0.39−$0.50
Surprise+4.0%+28.6%+102.9%+111.4%−30.2%+30.5%−60.0%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$344.0K$3.4M$12.7M$14.3M$5.1M$5.0M$5.9MPending
Estimate$2.1M$3.5M$6.5M$4.5M$4.5M$4.5M$5.7M$6.4M
Surprise−83.7%−2.7%+96.9%+217.3%+12.7%+11.3%+2.2%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.50 | — | — |
| Aug 2026 | −$0.39 | −$0.62 | −60.0% |
| May 2026 | −$0.59 | −$0.41 | +30.5% |
| Mar 2026 | −$0.43 | −$0.56 | −30.2% |
| Nov 2025 | −$1.14 | $0.13 | +111.4% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | −$0.50 | — | — | $6.4M | — | — | — |
| Aug 6, 2026 | −$0.39 | −$0.62 | −60.0% | $5.7M | $5.9M | +2.2% | −5.2% |
| May 12, 2026 | −$0.59 | −$0.41 | +30.5% | $4.5M | $5.0M | +11.3% | +3.1% |
| Mar 11, 2026 | −$0.43 | −$0.56 | −30.2% | $4.5M | $5.1M | +12.7% | −1.8% |
| Nov 14, 2025 | −$1.14 | $0.13 | +111.4% | $4.5M | $14.3M | +217.3% | −5.1% |
The latest year is open to everyone — the 34 quarters behind it read with an account. Sign in | |||||||
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Mar 11, 2025 | |||||||
| Nov 4, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 13, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 8, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 6, 2023 | |||||||
| Nov 7, 2022 | |||||||
| Aug 11, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 2, 2022 | |||||||
| Nov 12, 2021 | |||||||
| Aug 10, 2021 | |||||||
| May 7, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 9, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 13, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 7, 2019 | |||||||
| May 7, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 7, 2018 | |||||||
| Jun 15, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||